Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer

David Cappellen, Catherine De Oliveira, David Ricol, Sixtina de Medina, Jérôme Bourdin, Xavier Sastre-Garau, Dominique Chopin, Jean Paul Thiery, François Radvanyi, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics. ,vol. 23, pp. 18- 20 ,(1999) , 10.1038/12615

Teresa Helsten, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, Razelle Kurzrock, The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing Clinical Cancer Research. ,vol. 22, pp. 259- 267 ,(2016) , 10.1158/1078-0432.CCR-14-3212

Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy, Satish K. Tickoo, Samson W. Fine, Anuradha Gopalan, Ying-bei Chen, Arjun Balar, Jamie Riches, Bernard Bochner, Guido Dalbagni, Dean F. Bajorin, Victor E. Reuter, Matthew I. Milowsky, David B. Solit, Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. The Journal of Pathology. ,vol. 224, pp. 270- 279 ,(2011) , 10.1002/PATH.2892

Yann Neuzillet, Bas W. G. van Rhijn, Nadia L. Prigoda, Bharati Bapat, Liyang Liu, Peter J. Bostrom, Neil E. Fleshner, Brenda L. Gallie, Alexandre R. Zlotta, Michael A. S. Jewett, Theo H. van der Kwast, FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer Virchows Archiv. ,vol. 465, pp. 207- 213 ,(2014) , 10.1007/S00428-014-1596-4

Claude Billerey, Dominique Chopin, Marie-Hélène Aubriot-Lorton, David Ricol, Sixtina Gil Diez de Medina, Bas Van Rhijn, Marie-Pierre Bralet, Marie-Aude Lefrere-Belda, Jean-Baptiste Lahaye, Claude C. Abbou, Jacky Bonaventure, Elie Serge Zafrani, Theo van der Kwast, Jean Paul Thiery, Francois Radvanyi, Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors American Journal of Pathology. ,vol. 158, pp. 1955- 1959 ,(2001) , 10.1016/S0002-9440(10)64665-2

Cancer Genome Atlas Research Network, None, Comprehensive molecular characterization of urothelial bladder carcinoma Nature. ,vol. 507, pp. 315- 322 ,(2014) , 10.1038/NATURE12965

Vito Guagnano, Pascal Furet, Carsten Spanka, Vincent Bordas, Mickaël Le Douget, Christelle Stamm, Josef Brueggen, Michael R. Jensen, Christian Schnell, Herbert Schmid, Markus Wartmann, Joerg Berghausen, Peter Drueckes, Alfred Zimmerlin, Dirksen Bussiere, Jeremy Murray, Diana Graus Porta, Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase Journal of Medicinal Chemistry. ,vol. 54, pp. 7066- 7083 ,(2011) , 10.1021/JM2006222

Matthew I. Milowsky, Christian Dittrich, Ignacio Durán, Satinder Jagdev, Frederick E. Millard, Christopher J. Sweeney, Dean Bajorin, Linda Cerbone, David I. Quinn, Walter M. Stadler, Jonathan E. Rosenberg, Melissa Lochheed, Paramita Sen, Matthew Squires, Michael Shi, Cora N. Sternberg, Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma European Journal of Cancer. ,vol. 50, pp. 3145- 3152 ,(2014) , 10.1016/J.EJCA.2014.10.013

Silvia Hernández, Elena López-Knowles, Josep Lloreta, Manolis Kogevinas, Alex Amorós, Adonina Tardón, Alfredo Carrato, Consol Serra, Núria Malats, Francisco X. Real, Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas Journal of Clinical Oncology. ,vol. 24, pp. 3664- 3671 ,(2006) , 10.1200/JCO.2005.05.1771

Jeffrey S. Ross, Kai Wang, Depinder Khaira, Siraj M. Ali, Huge A.G. Fisher, Badar Mian, Tipu Nazeer, Julia A. Elvin, Norma Palma, Roman Yelensky, Doron Lipson, Vincent A. Miller, Philip J. Stephens, Vivek Subbiah, Sumanta K. Pal, Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. ,vol. 122, pp. 702- 711 ,(2016) , 10.1002/CNCR.29826